Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D. DiNardo, Marina Konopleva, Naval Daver et al.|American Journal of Hematology|2017Cited by 437
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330
Outcomes of <i>TP53</i>‐mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Marina Konopleva, Abhishek Maiti et al.|Cancer|2021Cited by 156